<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68668">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01719640</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-CNS</org_study_id>
    <nct_id>NCT01719640</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells in Central Nervous System Injury</brief_title>
  <official_title>Intrathecal Injection of Mesenchymal Stem Cells in Central Nervous System Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuzhou General Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central nervous system (CNS) injury leads to morbidity in patients, which has few good
      rehabilitation measures. Mesenchymal stem cells seem to have regenerative and
      tissue-repairing capabilities. The investigators design this study to infuse mesenchymal
      stem cells (MSCs) intrathecally to CNS injury patients, and observe the safety and efficacy
      by recording the change of nervous system scores, trying to prove the effect of MSC in
      rehabilitate CNS injury.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>life quality score</measure>
    <time_frame>1y</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>1y</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Central Nervous System Injury</condition>
  <arm_group>
    <arm_group_label>MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion of MSCs at day 0, 7, 14, 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>infusion of MSCs</intervention_name>
    <arm_group_label>MSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CNS injury &gt; 3 months

          -  age &gt; 18 years

          -  willing to give consent

        Exclusion Criteria:

          -  any contradiction to intrathecal infusion

          -  age &lt; 18 years

          -  CNS injury &lt; 3 months

          -  CNS injury &gt; 3 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuzhou General Hospital, Xiamen Univ</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 30, 2012</lastchanged_date>
  <firstreceived_date>October 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>central nervous system</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trauma, Nervous System</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
